AW
AMPH icon

Ankerstar Wealth’s Amphastar Pharmaceuticals AMPH Stock Holding History

Ankerstar Wealth’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15
Closed -$402 – 967
2025
Q4 		$402 Buy
+15
New +$386 ﹤0.01% 712

Other funds holding AMPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

Ankerstar Wealth's AMPH Position: Q1 2026 in Review

Ankerstar Wealth sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2026, closing a stake of 15 shares — an estimated $402 sold.

Ankerstar Wealth first reported a position in AMPH in Q4 2025 and held it in 1 quarter. The position peaked at $402 in Q4 2025. 215 funds tracked by Wall St. Rank hold AMPH as of Q1 2026.

  • Ankerstar Wealth reported no remaining Amphastar Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Ankerstar Wealth sold 15 Amphastar Pharmaceuticals shares in Q1 2026, an estimated $402.
  • Ankerstar Wealth first reported a position in Amphastar Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Ankerstar Wealth's Amphastar Pharmaceuticals position peaked at $402 in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2026.

Based on Ankerstar Wealth's 13F filing for Q1 2026, filed 14 May 2026.